Cipla Limited — Torsemide Exporter Profile
Indian Pharmaceutical Exporter · #4 for Torsemide · $805.9K export value · DGFT Verified
Cipla Limited is the #4 Indian exporter of Torsemide with $805.9K in export value and 48 verified shipments. Cipla Limited holds a 4.4% market share in Torsemide exports across 2 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Torsemide Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Torsemide?
Cipla Limited exports Torsemide to 2 countries. The largest destination is YEMEN accounting for 59.7% of Cipla Limited's Torsemide shipments. These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Torsemide from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CIPLAMEDICA PHARMACEUTICAL INDUSTRI | YEMEN | $383.3K | 12 |
| BREATHEFREE LANKA PVT LTD | SRI LANKA | $250.8K | 27 |
| MEDICA PHARMACEUTICAL INDUSTRIES L | YEMEN | $97.5K | 3 |
| BREATHEFREE LANKA PRIVATE LIMITED | SRI LANKA | $74.3K | 6 |
Cipla Limited supplies Torsemide to 4 buyers globally. The largest buyer is CIPLAMEDICA PHARMACEUTICAL INDUSTRI (YEMEN), followed by BREATHEFREE LANKA PVT LTD (SRI LANKA) and MEDICA PHARMACEUTICAL INDUSTRIES L (YEMEN). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Torsemide Export Value and How Much Does Cipla Limited Contribute?
India exported $17.7M worth of Torsemide through 1,997 shipments from 117 suppliers to 51 countries, serving 232 buyers globally. Cipla Limited contributes $805.9K to this total, accounting for 4.4% of India's Torsemide exports. Cipla Limited ships Torsemide to 2 countries through 4 buyers.
What Is the Average Shipment Value for Cipla Limited's Torsemide Exports?
Cipla Limited's average Torsemide shipment value is $16.8K per consignment, based on 48 shipments totaling $805.9K. The largest destination is YEMEN (59.7% of Cipla Limited's Torsemide exports).
How Does Cipla Limited Compare to Other Indian Torsemide Exporters?
Cipla Limited ranks #4 among 117 Indian Torsemide exporters with a 4.4% market share. The top 3 exporters are HETERO LABS LIMITED ($10.6M), AUROBINDO PHARMA LTD ($3.1M), MICRO LABS LIMITED ($1.9M). Cipla Limited processed 48 shipments to 2 destination countries.
What Torsemide Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| DYTOR - 10 TABLETS (TORSEMIDE TABLETS 10 | $168.3K | 13 |
| DYTOR 10 MG TABLETS (TORSEMIDE TABLETS10MG) (INV.QTY. 9297 PACK 10X10'S=929700 NOS) | $52.8K | 2 |
| DYTOR 20 MG TABLETS TORSEMIDE TABLETS20 MG INV.QTY.9643 PACK 10X10S=964300NOS | $48.2K | 1 |
| DYTOR 20 MG TABLETS TORSEMIDE TABLETS20 MG INV.QTY.9828 PACK 10 X 10S =982800 NOS | $47.9K | 1 |
| DYTOR 20 MG TABLETS TORSEMIDE TABLETS20 MG INV.QTY.9737 PACK 10 X 10S =973700 NOS | $47.5K | 1 |
| DYTOR 20 MG TABLETS TORSEMIDE TABLETS20 MG INV.QTY.9723 PACK 10 X 10S =972300 NOS | $47.4K | 1 |
| DYTOR 20 MG TABLETS ( TORSEMIDE TABLETS 20 MG) (INV.QTY. 9666 PACK 10X10'S=966600 NOS) | $44.6K | 1 |
| DYTOR 20 MG TABLETS TORSEMIDE TABLETS20 MG INV.QTY.8258 PACK 10 X 10S =825800 BOS | $40.3K | 1 |
| DYTOR-10 TABLETS TORSEMIDE TABLETS 10 M | $30.9K | 4 |
| DYTOR 10 MG TABLETS TORSEMIDE TABLETS 10 MG . INV.QTY.9849 PACK 10 X 10S =984900 NOS | $29.3K | 1 |
Cipla Limited exports 26 distinct Torsemide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is DYTOR - 10 TABLETS (TORSEMIDE TABLETS 10 with 13 shipments worth $168.3K.
How Does Cipla Limited Compare to Nearest Torsemide Exporters?
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | AUROBINDO PHARMA LTD | $3.1M | 116 | 2 | $26.7K |
| 3 | MICRO LABS LIMITED | $1.9M | 199 | 12 | $9.7K |
| 4 | CIPLA LIMITED ★ | $805.9K | 48 | 2 | $16.8K |
| 5 | AUROBINDO PHARMA LIMITED | $349.3K | 14 | 1 | $24.9K |
| 6 | LOTUS INTERNATIONAL | $202.5K | 52 | 1 | $3.9K |
Cipla Limited ranks #4 among 117 Indian Torsemide exporters. Average shipment value of $16.8K compared to the market average of $151.5K. The closest competitors by value are AUROBINDO PHARMA LTD and MICRO LABS LIMITED.
Which Indian Ports Ship Torsemide Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 409 | 20.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 255 | 12.8% |
| DELHI AIR | 164 | 8.2% |
| HYDERABAD ICD (INSNF6) | 144 | 7.2% |
| DELHI AIR CARGO ACC (INDEL4) | 138 | 6.9% |
| Bombay Air | 120 | 6.0% |
| HYDERABAD ICD | 110 | 5.5% |
| BANGALORE ACC (INBLR4) | 77 | 3.9% |
Geopolitical & Trade Policy Impact on Cipla Limited's Torsemide Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Torsemide, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Torsemide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Torsemide shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 48 individual customs records matching Cipla Limited exporting Torsemide, covering 26 formulations to 2 countries via 4 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 51+ countries, 232+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Torsemide Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Torsemide exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Torsemide Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Torsemide. For current shipment-level data, contact TransData Nexus.